Oral Anticancer Medication Toolkit

Oral formulations of chemotherapy and hormonal therapies have been used for decades and include many familiar agents, such as cyclophosphamide, methotrexate, and tamoxifen. Cancer treatment has experienced a rapid increase in oral anticancer medications, including cytotoxic agents, small-molecule inhibitors, and agents targeted at receptors that regulate cellular differentiation, growth, and survival. The expansion of oral therapies is remarkable, with 11 new approvals in 2020 and 14 in 2021 (U.S. FDA, 2022). The increase in oral anticancer medications calls on treatment centers to establish a workflow that ensures education, symptom management, and adherence monitoring are in the forefront.